RESEARCH DASHBOARD
-
RELEASE DATE
OCT 2025 -
Executive Pool
3123 -
PRICE
US$5850 -
EXPERT INPUTS
562 -
Companies
48 -
DATA Tables
306 -
Pages
605 -
Edition
10
WHAT'S BEHIND OUR DATA?
-
DOMAIN TRANSCRIPTS
140857226 -
BRANDS TRACKED
6080276 -
FEATURED COMPANIES
1729341 -
TOPICS COVERED
22574 -
MARKET SEGMENTS
82719 -
KEY INDUSTRIES
91 -
CURATION TEAM
1574 -
DECISION MAKERS
4761909
EXECUTIVES TRACKED (2473)
-
CXO
242 -
VICE PRESIDENT
279 -
DIRECTOR
768 -
MANAGER
884MARKETING
300
EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
OCT 2025
-
EDITION 10
-
TABLES 306
-
REGIONS 26
-
SEGMENTS 10
-
PAGES 605
-
US$ 5850
-
MCP16923
-
JOIN OUR PANEL
SELECT LICENSE TYPE
HIGHLIGHTS & REPORT INDEX
Global Lung Cancer Diagnostics Market to Reach $4.4 Billion by 2030
The global market for Lung Cancer Diagnostics estimated at US$2.8 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 7% over the analysis period 2023-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Molecular Tests segment is estimated at 7.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $893.7 Million, While China is Forecast to Grow at 9.3% CAGR
The Lung Cancer Diagnostics market in the U.S. is estimated at US$893.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$570.4 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 6.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$490.8 Million by the year 2030.
Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
SCOPE OF STUDY
The report analyzes the Lung Cancer Diagnostics market by the following Segments, and Geographic Regions/Countries:
Segments:
Test Type (Imaging Tests, Molecular Tests, Biopsy, Sputum Cytology, Other Test Types); Cancer Type (Non-Small-Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Other End-Uses).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
Myriad Genetics, Inc.; F. Hoffmann-La Roche AG; Biocartis NV; Epigenomics AG; Biodesix, Inc.; Exosome Diagnostics, Inc.; Admera Health; Dr Lal PathLabs Ltd.; Guardant Health, Inc.; Oncimmune Holding PLC; Blueprint Genetics OY; CellMax Life, Inc.; Circulogene; BGI Genomics Co Ltd.; Inivata Ltd.
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Tariff Impact on Global Supply Chain Patterns |
| A Prelude to Lung Cancer Diagnostics |
| Early Detection of Lung Cancer: Screening Guidelines and Considerations |
| Economic Frontiers: Trends, Trials & Transformations |
| EXHIBIT : In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025 |
| EXHIBIT: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025 |
| EXHIBIT: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025 |
| Global Market Overview |
| Lung Cancer Diagnostics Market Set for Tremendous Growth |
| Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types |
| Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth |
| US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth |
| Competitive Landscape |
| Lung Cancer Diagnostics – Global Key Competitors Percentage Market Share in 2025 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 48 Players Worldwide in 2025 (E) |
| Recent Market Activity |
| Select Innovations in Recent Years |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses |
| Age-Standardized Lung Cancer Rates for Select Countries |
| Age-Standardized Lung Cancer Rates in Men for Select Countries |
| Age Standardized Lung Cancer Rates in Women for Select Countries |
| Lung Cancer-Specific Biomarkers to Spur Market Growth |
| Select Lung Cancer Biomarkers |
| New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study |
| Advancements and Research Initiatives in Lung Cancer Diagnostics Space |
| EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients |
| A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests |
| New Product Launches/Approvals in the Lung Cancer Diagnostics |
| Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs |
| Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years |
| High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer |
| Increasing Number of Awareness Programs for Lung Cancer and Symptoms |
| Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics |
| Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer |
| Cancer Prone Sites based on Age |
| Table: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
| Leveraging AI for Early Detection of Lung Cancer |
| New Biomarker Innovations and Advancements in Lung Cancer Treatment |
| Transformative Technologies Advancing Lung Cancer Detection and Treatment |
| Advancing Lung Cancer Diagnosis with the Ion Robotic Bronchoscopy System |
| Advancing Lung Cancer Diagnosis with the Ion Robotic Bronchoscopy System |
| Revolutionizing Lung Cancer Diagnosis with Blood-Based Biomarkers |
| Lung Cancer Screening and Non-Invasive Biomarkers: Addressing Global Challenges and Advancements in Early Detection |
| Inhalable Nanosensors and Urine Test Offer Accessible Early Screening |
| Enhancing Lung Cancer Detection with AI and Advanced CT Technology |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Sputum Cytology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Molecular Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Small-Cell Lung Cancer (SCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Lung Cancer Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| Lung Cancer Stats |
| Reimbursement and Insurance Coverage for Lung Cancer Screening in the US |
| Market Analytics |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| USA 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| USA 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| USA 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Canada 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Canada 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Canada 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| JAPAN |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Japan 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Japan 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Japan 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| CHINA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| China 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| China 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| China 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| EUROPE |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| FRANCE |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| France 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| France 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| France 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| GERMANY |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Germany 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Germany 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Germany 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Italy 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Italy 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Italy 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| UNITED KINGDOM |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| TABLE: UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UK 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UK 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UK 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Spain 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Spain 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Spain 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Russia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Russia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Russia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Europe 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| ASIA-PACIFIC |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| AUSTRALIA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E) |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Australia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Australia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Australia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| INDIA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E) |
| Rise in Incidence of Lung Cancer in India |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| India 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| India 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| India 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| South Korea 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| South Korea 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| South Korea 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Asia-Pacific 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| LATIN AMERICA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E) |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Argentina 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Argentina 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Argentina 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Brazil 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Brazil 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Brazil 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Mexico 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Mexico 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Mexico 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Latin America 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| MIDDLE EAST |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E) |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Iran 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Iran 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Iran 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Israel 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Israel 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Israel 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Saudi Arabia 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UAE 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UAE 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| UAE 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Rest of Middle East 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| AFRICA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E) |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Africa 16-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2014, 2025 & 2030 |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Africa 16-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2014, 2025 & 2030 |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR |
| Africa 16-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2014, 2025 & 2030 |
| (including Divisions/Subsidiaries - 48) |